|
End-of-day quote
Korea S.E.
17/11/2026
|
5-day change | 1st Jan Change | ||
| 2,13,000.00 KRW | -0.70% |
|
+1.43% | +23.56% |
| 10/11 | Celltrion's Stekima Wins EU Backing for Expanded Use in Children | MT |
| 03/11 | Celltrion Gets European Approval for Rheumatoid Arthritis Drug Trial | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CELLTRION, INC. | Other Biotechnology & Medical Research | -0.70% | +1.43% | +23.56% | +14.05% | +13.13% | 3.67TCr |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















